症状性静脉结扎的血管内再通与支架重建:技术与结局
单中心回顾性研究纳入9例症状性静脉结扎患者,行血管内再通与支架重建,初始单次再通率100%,主要/次要通畅率88.9%,临床改善率88.9%,无死亡,提示该技术安全有效。
要点
- 症状性静脉结扎可行血管内再通与支架重建,初始单次再通率100%。
- 主要/次要通畅率88.9%,临床改善率88.9%,完全症状缓解率66.7%。
- 严重不良事件发生率10.0%(SIR D类),无死亡。
核心结论
- 血管内再通与重建是症状性静脉结扎安全有效的治疗方法。
研究设计与样本
- 单中心回顾性研究,纳入2014年1月至2024年1月间9例(平均年龄52.9岁)因症状性静脉结扎行血管内再通与支架重建的患者。
主要发现
- 初始单次再通在9例患者中均成功(100%),共行10次手术,1例因早期血栓形成需再次干预。
- 1例(11.1%)发生早期支架闭塞且无法再通,其余重建血管保持通畅(主要/次要通畅率88.9%)。
- 平均影像随访466.4±500.3天,平均临床随访1,086.2±717.5天;主要不良事件1例(10.0%,SIR D类),轻微不良事件1例(10.0%,SIR A类)。
- 临床改善8例(88.9%),其中完全症状缓解6例(66.7%),无死亡。
临床怎么用
- 对于症状性静脉结扎患者,可考虑血管内再通与支架重建作为治疗选择。
局限性
- 单中心回顾性研究,样本量小(9例),随访时间变异大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To report techniques, adverse events, and outcomes of endovascular recanalization and stent reconstruction for symptomatic venous ligation. METHODS: In this single-center retrospective study, 9 patients (mean age, 52.9), underwent endovenous recanalization and stent reconstruction for symptomatic venous ligation between January 2014 and January 2024. Patients presented with clinical-etiology-anatomy-pathophysiology 3 (55.6%), 4 (11.1%), and 5 (33.3%) disease. Ligation sites commonly involved the external iliac (66.7%) or femoral veins (44.4%); 5 patients had multisegment ligation. Etiologies included surgical injury (44.4%), trauma (22.2%), chronic venous thrombosis (22.2%), and malignant resection (11.1%). Procedural techniques, recanalization methods, stent selection, adverse events, patency, and clinical outcomes were recorded. RESULTS: Primary single-session recanalization was achieved in 9 patients (100%). Ten procedures were performed, as 1 patient required reintervention for early thrombosis. Sharp extravascular techniques were required in 6 procedures (60%). Twenty-six stents were deployed (Wallstents, cTAG devices, SMART stents), with a mean of 2.9 ± 2.5 stents per patient and mean stent diameter of 15.5 ± 3.2 mm. One patient (11.1%) developed early stent occlusion and was unable to be recanalized. All other reconstructions remained patent (primary/secondary patency 88.9%). Mean imaging follow-up was 466.4 ± 500.3 days, and mean clinical follow-up was 1,086.2 ± 717.5 days. Adverse events included 1 major (10.0%; Society of Interventional Radiology (SIR) class D) and 1 minor (10.0%; SIR class A). Clinical improvement occurred in 8 patients (88.9%), including complete symptom resolution in 6 (66.7%). No mortality occurred. CONCLUSION: Endovenous recanalization and reconstruction is a safe and effective treatment for symptomatic venous ligation.
引用
- Woerner A, Umapathy MP, Chick JFB, et al. Techniques and Outcomes of Recanalization and Reconstruction for Treatment of Symptomatic Venous Ligation. Ann Vasc Surg. 2026. PMID: 41651165. doi:10.1016/j.avsg.2026.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。